Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports

  title={Covid-19: Pfizer’s paxlovid is 89\% effective in patients at risk of serious illness, company reports},
  author={Elisabeth Mahase},
In the study, trial participants were randomised 1:1, with half receiving paxlovid and the other half receiving a placebo orally every 12 hours for five days. Of those who were treated within three days of symptom onset, 0.8% (3/389) of patients who received paxlovid were admitted to hospital up to day 28 after randomisation, with no deaths. In comparison, 7% (27/385) of patients who received placebo were admitted, with seven deaths. The statistical significance of these results was reported as… 
Phamrmacoligical Therapies for COVID-19: A Comprehensive Review from 2022 Updated Nih, IDSA and ICMR Guidelines
This review article gives a comprehensive update on various pharmacological therapies in the light of recently published standard treatment guidelines based on large clinical trials for the treatment of COVID-19.
Pandora’s box: Paxlovid, prescribing, pharmacists and pandemic
  • J. Roberts, A. Duncan, K. Cairns
  • Medicine
    Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia
  • 2022
Oral antivirals are a potential ‘game changer’ for healthcare provision during the ongoing coronavirus disease 2019 (COVID-19) pandemic and specific considerations exist for the prescribing and dispensing of Paxlovid, a combination of nirmatrelvir and ritonavir.
Pro108Ser mutation of SARS-CoV-2 3CLpro reduces the enzyme activity and ameliorates the clinical severity of COVID-19
These findings of the attenuated clinical course of COVID-19 in patients infected with SARS-CoV-2 strains with reduced 3CLpro enzymatic activity greatly endorses the promising result of the aforementioned clinical trial of the3CLpro inhibitor.
Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients
It was showed that lithium was able to reduce the number of days of hospital and intensive care unit admission as well as the risk of death, reduces inflammatory cytokine levels by preventing cytokine storms, and also reduced the long COVID syndromes.
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial.
In this randomized clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease and the study findings do not support the use of iver mectin for patients with CO VID-19.
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?
Drug repurposing for the treatment of COVID-19
Adrenomedullin Therapy in Moderate to Severe COVID-19
The results of this study strongly suggest that AM could be an alternative therapy in severe inflammation disorders, including COVID-19, and exogenous AM administration reduced inflammation and related organ damage in rodent models.
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Vaccinations against SARS-CoV-2 has shown high efficacy in reducing community transmission, hospitalisation and deaths due to severe COVID-19 disease in the general population, but immunosuppressed/haematology patients may have lower sero-responsiveness to vaccinations.


Covid-19: UK becomes first country to authorise antiviral molnupiravir
Recruitment to the trial was stopped on the advice of the independent data monitoring committee because of the positive results, a release said.